- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06153251
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
February 23, 2024 updated by: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
130
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: First line of the email MUST contain the NCT# and Site#
Study Contact Backup
- Name: BMS Study Connect www.BMSStudyConnect.com
- Phone Number: 855-907-3286
- Email: Clinical.Trials@bms.com
Study Locations
-
-
-
Paris, France, 75010
- Not yet recruiting
- Local Institution - 0019
-
Contact:
- Site 0019
-
-
-
-
-
Köln, Germany, 50937
- Not yet recruiting
- Local Institution - 0017
-
Contact:
- Site 0017
-
Wuerzburg, Germany, 97080
- Not yet recruiting
- Local Institution - 0018
-
Contact:
- Site 0018
-
-
-
-
-
Salamanca, Spain, 37007
- Not yet recruiting
- Local Institution - 0014
-
Contact:
- Site 0014
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Not yet recruiting
- Local Institution - 0015
-
Contact:
- Site 0015
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294-3300
- Recruiting
- University of Alabama at Birmingham
-
Contact:
- Luciano Costa, Site 0001
- Phone Number: 205-934-9695
-
-
California
-
Duarte, California, United States, 91010
- Not yet recruiting
- Local Institution - 0003
-
Contact:
- Site 0003
-
San Francisco, California, United States, 94143
- Not yet recruiting
- Local Institution - 0011
-
Contact:
- Site 0011
-
Stanford, California, United States, 94305
- Not yet recruiting
- Local Institution - 0006
-
Contact:
- Site 0006
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Recruiting
- Colorado Blood Cancer Institute
-
Contact:
- Tara Gregory, Site 0013
- Phone Number: 720-754-4800
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Not yet recruiting
- Local Institution - 0005
-
Contact:
- Site 0005
-
-
Florida
-
Tampa, Florida, United States, 33612
- Not yet recruiting
- Local Institution - 0016
-
Contact:
- Site 0016
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center
-
Contact:
- Sham Mailankody, Site 0004
- Phone Number: 646-608-3712
-
New York, New York, United States, 10029
- Not yet recruiting
- Local Institution - 0010
-
Contact:
- Site 0010
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Not yet recruiting
- Local Institution - 0008
-
Contact:
- Site 0008
-
Nashville, Tennessee, United States, 37203
- Not yet recruiting
- Local Institution - 0020
-
Contact:
- Site 0020
-
-
Washington
-
Seattle, Washington, United States, 98104
- Not yet recruiting
- Local Institution - 0012
-
Contact:
- Site 0012
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Participants must have a diagnosis of multiple myeloma with relapsed and/or refractory disease.
- Participants must have confirmed progressive disease on or within 12 months (measured from the last dose) of completing treatment with the last anti-myeloma treatment regimen before study entry.
- Participants in Part A and Part B Cohort 1 must have received at least 3 prior anti-myeloma treatment regimens, including a proteasome inhibitor and immunomodulatory agent.
- Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Participants must have adequate organ function.
Exclusion Criteria:
- Participants must not have any known active or history of central nervous system (CNS) involvement of multiple myeloma.
- Participants must not have active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, or clinically significant amyloidosis.
- Participants must not have a history or presence of clinically significant CNS pathology such as seizure disorder, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, or cerebellar disease, or presence of clinically active psychosis.
Other protocol-defined inclusion/exclusion criteria apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Administration of BMS-986453
|
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with serious adverse events (SAEs)
Time Frame: Up to 2 years
|
Up to 2 years
|
Number of participants with AEs leading to discontinuation
Time Frame: Up to 2 years
|
Up to 2 years
|
Number of participants with treatment-emergent adverse events (AEs)
Time Frame: Up to 2 years
|
Up to 2 years
|
Number of participants with AEs leading to death
Time Frame: Up to 2 years
|
Up to 2 years
|
Number of participants with dose-limiting toxicities (DLTs)
Time Frame: Up to 2 years
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: Up to 2 years
|
Up to 2 years
|
|
Progression-free survival (PFS)
Time Frame: Up to 2 years
|
Up to 2 years
|
|
Overall response rate (ORR)
Time Frame: Up to 2 years
|
Up to 2 years
|
|
Duration of response (DOR)
Time Frame: Up to 2 years
|
Up to 2 years
|
|
Time to response (TTR)
Time Frame: Up to 2 years
|
Up to 2 years
|
|
Complete response rate (CRR)
Time Frame: Up to 2 years
|
Up to 2 years
|
|
Area under the blood concentration-time curve from time zero to 28 days after dosing (AUC(0-28D))
Time Frame: Up to 2 years
|
Up to 2 years
|
|
Maximum observed concentration (Cmax)
Time Frame: Up to 2 years
|
Up to 2 years
|
|
Time of maximum observed concentration (Tmax)
Time Frame: Up to 2 years
|
Up to 2 years
|
|
Number of participants with very good partial response (VGPR) or better
Time Frame: Up to 2 years
|
Up to 2 years
|
|
Time to complete response (TTCR)
Time Frame: Up to 2 years
|
Up to 2 years
|
|
Duration of complete response (DOCR)
Time Frame: Up to 2 years
|
Up to 2 years
|
|
Persistence of BMS-986453 in peripheral blood
Time Frame: Up to 2 years
|
Defined as a transgene count greater than or equal to the lower limit of detection (LLOD)
|
Up to 2 years
|
Expansion rate
Time Frame: Up to 2 years
|
Defined as Cmax divided by Tmax
|
Up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 23, 2024
Primary Completion (Estimated)
November 29, 2027
Study Completion (Estimated)
November 29, 2027
Study Registration Dates
First Submitted
November 22, 2023
First Submitted That Met QC Criteria
November 22, 2023
First Posted (Actual)
December 1, 2023
Study Record Updates
Last Update Posted (Actual)
February 26, 2024
Last Update Submitted That Met QC Criteria
February 23, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
- Fludarabine
Other Study ID Numbers
- CA119-0002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria.
Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-andresearch/disclosure-commitment.html
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed and/or Refractory Multiple Myeloma
-
BeBetter Med IncCompletedRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Non-Hodgkin's LymphomaChina
-
AmgenActive, not recruitingRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid LeukemiaUnited States, Australia, Japan, Germany, Canada
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory Non-Hodgkin Lymphoma | Relapsed or Refractory Chronic Lymphocytic LeukemiaUnited Kingdom, Spain, France, Australia
-
Oncopeptides ABTerminatedRelapsed Multiple Myeloma | Relapsed-Refractory Multiple MyelomaSerbia, Greece, Russian Federation, Czechia, Bulgaria, Georgia, Norway, Poland, Spain, Ukraine, Germany
-
Novartis PharmaceuticalsCompletedRefractory Multiple Myeloma | Multiple Myeloma in Relapse | Relapsed and Bortezomib Refractory Multiple MyelomaUnited States
-
Oncopeptides ABTerminatedRelapsed and/or Relapsed-refractory Multiple MyelomaUnited States, Netherlands, Denmark, Sweden, Italy
-
University of NebraskaM.D. Anderson Cancer CenterTerminatedCabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple MyelomaMultiple Myeloma | Refractory Multiple Myeloma | Relapsed/Refractory Multiple MyelomaUnited States
-
University of LeedsCompletedRelapsed or Refractory Multiple MyelomaUnited Kingdom
-
Memorial Sloan Kettering Cancer CenterExelixisCompletedRelapsed or Refractory Multiple MyelomaUnited States
-
Janssen Research & Development, LLCRecruitingRelapsed or Refractory Multiple MyelomaKorea, Republic of, Italy, Germany, France, Japan, Israel, Belgium, Denmark, Sweden, Canada, Spain, Czechia, Poland, Australia, Netherlands, United Kingdom, India, China
Clinical Trials on Cyclophosphamide
-
Children's Hospital Los AngelesLucile Packard Children's HospitalTerminatedMetabolic Diseases | Stem Cell Transplantation | Chronic Granulomatous Disease | Bone Marrow Transplantation | Thalassemia | Wiskott-Aldrich Syndrome | Genetic Diseases | Peripheral Blood Stem Cell Transplantation | Pediatrics | Diamond-Blackfan Anemia | Allogeneic Transplantation | Combined Immune Deficiency | X-linked Lymphoproliferative Disease
-
Medical College of WisconsinNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedAnemia, AplasticUnited States
-
Columbia UniversityUnknownSevere Combined Immunodeficiency | Fanconi Anemia | Bone Marrow Failure | OsteopetrosisUnited States
-
National Cancer Institute, NaplesImmatics Biotechnologies GmbH; CureVac; European Commission -FP7-Health-2013-Innovation-1CompletedHepatocellular CarcinomaBelgium, Germany, Italy, Spain, United Kingdom
-
Mahidol UniversityTerminatedRenal Insufficiency | InfectionThailand
-
Eisai Inc.CompletedBreast Cancer | Ovarian Cancer | Prostate Cancer | Colon Cancer | Renal CancerUnited States
-
Centre Oscar LambretCompleted
-
Baylor Research InstituteCompletedMalignant Melanoma Stage IVUnited States
-
University of Turin, ItalyUnknown
-
Merck KGaA, Darmstadt, GermanyCompleted